Erratum: Epstein-Barr Virus-Encoded Latent Membrane Protein 2A Promotes the Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma via Metastatic Tumor Antigen 1 and Mechanistic Target of Rapamycin Signaling Induction (Journal of Virology (2014) 88: 20 (11872-11885) DOI: 10.1128/jvi.01867-14);Epstein-Barr virus-encoded latent membrane protein 2A promotes the epithelial-mesenchymal transition in nasopharyngeal carcinoma via metastatic tumor antigen 1 and mechanistic target of rapamycin signaling induction

Journal of Virology

Volumn 88, Issue 20, 2014, Pages 11872-11885

  Lin, Zhe ^a   Wan, Xin ^a   Jiang, Runqiu ^b   Deng, Lei ^b   Gao, Yun ^b   Tang, Junwei ^b   Yang, Yu ^b   Zhao, Wei ^a   Yan, Xin ^a   Yao, Kun ^a   Sun, Beicheng ^b   Chen, Yun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; LATENT MEMBRANE PROTEIN 2A; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR INK 128; METASTATIC TUMOR ANTIGEN 1; MYC PROTEIN; SMALL INTERFERING RNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS PROTEIN; WNT1 PROTEIN; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; HISTONE DEACETYLASE; MATRIX PROTEIN; MTA1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PRIMER DNA; REPRESSOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; CELL NUCLEUS; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISTANT METASTASIS; DRUG PROTEIN BINDING; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENE ACTIVATION; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE LOCATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LMP2A GENE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MTA1 GENE; MTOR GENE; NASOPHARYNX CARCINOMA; NONHUMAN; ONCOGENE; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION; MIDDLE AGED; NASOPHARYNX TUMOR; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY;

BASE SEQUENCE; DNA PRIMERS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HISTONE DEACETYLASES; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; REPRESSOR PROTEINS; TOR SERINE-THREONINE KINASES; VIRAL MATRIX PROTEINS;

EID: 84907913631     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/jvi.00399-24     Document Type: Erratum

References (53)

1. Wei WI, Sham JST. 2005. Nasopharyngeal carcinoma. Lancet 365:2041-2054. http://dx.doi.org/10.1016/S0140-6736(05)66698-6.
2. Chan A, Teo P, Ngan R, Leung T, Lau W, Zee B, Leung S, Cheung F, Yeo W, Yiu H. 2002. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J. Clin. Oncol. 20:2038-2044. http://dx.doi.org/10.1200/JCO.2002.08.149.
3. Wang J, Guo L-P, Chen L-Z, Zeng Y-X, Lu SH. 2007. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 67:3716-3724. http://dx.doi.org/10.1158 /0008-5472.CAN-06-4343.
4. Langendijk J, Leemans CR, Buter J, Berkhof J, Slotman B. 2004. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J. Clin. Oncol. 22:4604-4612. http://dx.doi.org/10.1200/JCO.2004.10.074.
5. Chua DT, Sham JS, Au GK. 2003. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol. 39:361-366. http://dx.doi.org/10.1016/S1368-8375(02)00120-3.
6. Kang Y, Massagué J. 2004. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118:277-279. http://dx.doi.org/10.1016 /j.cell.2004.07.011.
7. Grünert S, Jechlinger M, Beug H. 2003. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol. 4:657-665. http://dx.doi.org/10.1038/nrm1175.
8. Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, Damiani LA, Tessema M, Leng S, Belinsky SA. 2011. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. 71:3087-3097. http://dx.doi.org/10.1158 /0008-5472.CAN-10-3035.
9. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M. 2008. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 133:704-715. http://dx.doi.org/10.1016/j.cell.2008.03.027.
10. Brooks L, Yao Q, Rickinson A, Young L. 1992. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 66:2689-2697.
11. Pegtel DM, Subramanian A, Sheen T-S, Tsai C-H, Golub TR, Thorley-Lawson DA. 2005. Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis. J. Virol. 79:15430-15442. http://dx.doi.org/10.1128/JVI.79.24.15430-15442.2005.
12. Kong Q-L, Hu L-J, Cao J-Y, Huang Y-J, Xu L-H, Liang Y, Xiong D, Guan S, Guo B-H, Mai H-Q. 2010. Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog. 6:e1000940. http://dx.doi.org/10.1371 /journal.ppat.1000940.
13. Lu J, Lin W-H, Chen S-Y, Longnecker R, Tsai S-C, Chen C-L, Tsai C-H. 2006. Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J. Biol. Chem. 281: 8806-8814. http://dx.doi.org/10.1074/jbc.M507305200.
14. Moody CA, Scott RS, Amirghahari N, Nathan C-A, Young LS, Dawson CW, Sixbey JW. 2005. Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. J. Virol. 79:5499-5506. http://dx.doi.org/10.1128/JVI.79.9.5499-5506.2005.
15. Shaw RJ, Cantley LC. 2006. Ras, PI (3) K and mTOR signalling controls tumour cell growth. Nature 441:424-430. http://dx.doi.org/10.1038 /nature04869.
16. O'Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66:1500-1508. http://dx.doi.org/10.1158/0008-5472.CAN-05-2925.
17. Chiang GG, Abraham RT. 2007. Targeting the mTOR signaling network in cancer. Trends Mol. Med. 13:433-442. http://dx.doi.org/10.1016/j.molmed.2007.08.001.
18. Seeliger H, Guba M, Kleespies A, Jauch K-W, Bruns CJ. 2007. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metast. Rev. 26:611-621. http://dx.doi.org/10.1007/s10555-007-9077-8.
19. Fukuda M, Longnecker R. 2004. Latent membrane protein 2A inhibits transforming growth factor-β1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J. Virol. 78:1697-1705. http://dx.doi.org/10.1128/JVI.78.4.1697-1705.2004.
20. Scholle F, Bendt KM, Raab-Traub N. 2000. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J. Virol. 74:10681-10689. http://dx.doi.org/10.1128/JVI.74.22.10681-10689.2000.
21. Toh Y, Pencil SD, Nicolson GL. 1994. A novel candidate metastasisassociated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J. Biol. Chem. 269:22958-22963.
22. Li W-F, Liu N, Cui R-X, He Q-M, Chen M, Jiang N, Sun Y, Zeng J, Liu L-Z, Ma J. 2012. Nuclear overexpression of metastasis-associated protein 1 correlates significantly with poor survival in nasopharyngeal carcinoma. J. Transl. Med. 10:78. http://dx.doi.org/10.1186/1479-5876-10-78.
23. Gururaj AE, Singh RR, Rayala SK, Holm C, den Hollander P, Zhang H, Balasenthil S, Talukder AH, Landberg G, Kumar R. 2006. MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proc. Natl. Acad. Sci. USA 103:6670-6675. http://dx.doi.org/10.1073/pnas.0601989103.
24. Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE, Hautmann RE, Sanda MG, Giehl K. 2004. The role of metastasisassociated protein 1 in prostate cancer progression. Cancer Res. 64:825-829. http://dx.doi.org/10.1158/0008-5472.CAN-03-2755.
25. Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Yukiue H, Kaji M, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y. 2002. Expression of the MTA1 mRNA in advanced lung cancer. Lung Cancer 35:149-154. http: //dx.doi.org/10.1016/S0169-5002(01)00329-4.
26. Toh Y, Ohga T, Endo K, Adachi E, Kusumoto H, Haraguchi M, Okamura T, Nicolson GL. 2004. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int. J. Cancer 110:362-367. http: //dx.doi.org/10.1002/ijc.20154.
27. Toh Y, Oki E, Oda S, Tokunaga E, Ohno S, Maehara Y, Nicholson G, Sugimachi K. 1997. Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Int. J. Cancer 74: 459-463.
28. Hofer M, Menke A, Genze F, Gierschik P, Giehl K. 2004. Expression of MTA1 promotes motility and invasiveness of PANC-1 pancreatic carcinoma cells. Br. J. Cancer 90:455-462. http://dx.doi.org/10.1038/sj.bjc.6601535.
29. Toh Y, Kuwano H, Mori M, Nicolson G, Sugimachi K. 1999. Overexpression of metastasis-associated MTA1 mRNA in invasive oesophageal carcinomas. Br. J. Cancer 79:1723. http://dx.doi.org/10.1038/sj.bjc.6690274.
30. Pakala SB, Singh K, Reddy SDN, Ohshiro K, Li D-Q, Mishra L, Kumar R. 2011. TGF-β1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells. Oncogene 30:2230-2241. http://dx.doi.org/10.1038/onc.2010.608.
31. Zhang XY, DeSalle LM, Patel JH, Capobianco AJ, Yu D, Thomas-Tikhonenko A, McMahon SB. 2005. Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc. Natl. Acad. Sci. USA 102:13968-13973. http://dx.doi.org/10.1073 /pnas.0502330102.
32. Zhu W, Cai M-Y, Tong Z-T, Dong S-S, Mai S-J, Liao Y-J, Bian X-W, Lin MC, Kung H-F, Zeng Y-X. 2012. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymal transition. Gut 61:562-575. http://dx.doi.org/10.1136/gutjnl-2011-300207.
33. Yan D, Avtanski D, Saxena NK, Sharma D. 2012. Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3-and MTA1/Wnt1 protein-dependent pathways. J. Biol. Chem. 287:8598-8612. http://dx.doi.org/10.1074/jbc.M111.322800.
34. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ. 2012. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485:55-61. http://dx.doi.org/10.1038/nature10912.
35. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, Pandolfi PP. 2004. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10:484-486. http://dx.doi.org/10.1038/nm1042.
36. Qian H, Yu J, Li Y, Wang H, Song C, Zhang X, Liang X, Fu M, Lin C. 2007. RNA interference of metastasis-associated gene 1 inhibits metastasis of B16F10 melanoma cells in a C57BL/6 mouse model. Biol. Cell 99:573-581. http://dx.doi.org/10.1042/BC20060130.
37. Mizushima T, Nakagawa H, Kamberov YG, Wilder EL, Klein PS, Rustgi AK. 2002. Wnt-1 but not epidermal growth factor induces β-catenin/Tcell factor-dependent transcription in esophageal cancer cells. Cancer Res. 62:277-282.
38. Huang C-L, Liu D, Ishikawa S, Nakashima T, Nakashima N, Yokomise H, Kadota K, Ueno M. 2008. Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. Eur. J. Cancer 44:2680-2688. http://dx.doi.org/10.1016/j.ejca.2008.08.004.
39. Kumar R, Balasenthil S, Pakala SB, Rayala SK, Sahin AA, Ohshiro K. 2010. Metastasis-associated protein 1 short form stimulates Wnt1 pathway in mammary epithelial and cancer cells. Cancer Res. 70:6598-6608. http://dx.doi.org/10.1158/0008-5472.CAN-10-0907.
40. Fukuda M, Longnecker R. 2007. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway. J. Virol. 81:9299-9306. http://dx.doi.org/10.1128/JVI.00537-07.
41. Pearce L, Alton G, Richter D, Kath J, Lingardo L, Chapman J, Hwang C, Alessi D. 2010. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem. J. 431:245-255. http://dx.doi.org/10.1042/BJ20101024.
42. Li D-Q, Pakala SB, Nair SS, Eswaran J, Kumar R. 2012. Metastasisassociated protein 1/nucleosome remodeling and histone deacetylase complex in cancer. Cancer Res. 72:387-394. http://dx.doi.org/10.1158 /0008-5472.CAN-11-2345.
43. Reddy SDN, Pakala SB, Molli PR, Sahni N, Karanam NK, Mudvari P, Kumar R. 2012. Metastasis-associated protein 1/histone deacetylase 4-nucleosome remodeling and deacetylase complex regulates phosphatase and tensin homolog gene expression and function. J. Biol. Chem. 287: 27843-27850. http://dx.doi.org/10.1074/jbc.M112.348474.
44. Kumar R, Balasenthil S, Manavathi B, Rayala SK, Pakala SB. 2010. Metastasis-associated protein 1 and its short form variant stimulates Wnt1 transcription through promoting its derepression from Six3 corepressor. Cancer Res. 70:6649-6658. http://dx.doi.org/10.1158/0008-5472.CAN-10-0909.
45. Moon H-E, Cheon H, Chun K-H, Lee SK, Kim Y-S, Jung B-K, Park J, Kim S-H, Jeong J-W, Lee M-S. 2006. Metastasis-associated protein 1 enhances angiogenesis by stabilization of HIF-1α. Oncol. Rep. 16:929-935. http://dx.doi.org/10.3892/or.16.4.929.
46. Lin C-J, Cencic R, Mills JR, Robert F, Pelletier J. 2008. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res. 68:5326-5334. http://dx.doi.org/10.1158/0008-5472.CAN-07-5876.
47. Gao W, Li JZH, Chan JYW, Ho WK, Wong T-S. 2012. mTOR pathway and mTOR inhibitors in head and neck cancer. ISRN Otolaryngol. 2012: 953089. http://dx.doi.org/10.5402/2012/953089.
48. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, Lee EY, Weiss HL, O'Connor KL, Gao T. 2011. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 71:3246-3256. http://dx.doi.org/10.1158/0008-5472.CAN-10-4058.
49. Sarbassov DD, Ali SM, Sabatini DM. 2005. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17:596-603. http://dx.doi.org/10.1016/j.ceb.2005.09.009.
50. Bultema R, Longnecker R, Swanson-Mungerson M. 2009. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis. Oncogene 28: 1471-1476. http://dx.doi.org/10.1038/onc.2008.492.
51. Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD. 2014. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat. Rev. 40: 190-196. http://dx.doi.org/10.1016/j.ctrv.2013.04.005.
52. Garcia-Garcia C, Ibrahim YH, Serra V, Calvo MT, Guzman M, Grueso J, Aura C, Perez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M. 2012. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin. Cancer Res. 18:2603-2612. http://dx.doi.org/10.1158/1078-0432.CCR-11-2750.
53. O'Sullivan B, Yu E. 2010. Staging of nasopharyngeal carcinoma, p 309-322. In Lee N, Kong L (ed), Nasopharyngeal cancer. Springer, New York, NY.